ClinicalTrials.gg
CompletedNCT03659929Updated Sep 3, 2024Results posted

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

A Phase 3 interventional study of Amphetamine Sulfate and Placebo in Attention Deficit Hyperactivity Disorder, sponsored by Arbor Pharmaceuticals, Inc.. Completed at 31 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Arbor Pharmaceuticals, Inc. (part of Azurity Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
70th of 706
320 · median 70
Started
2018
with 36 others
Phase 3
121 of 807
4 open now
Registered
544th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 70th largest by enrollment of the 706 interventional ones that give a count, is one of 37 that started in 2018, is one of 121 in phase 3, and was the 544th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

The purpose of the AR19.004 study is to assess the efficacy of AR19 compared to placebo using the Adult ADHD Investigator Symptom Rating Scale (AISRS)

Read the detailed description

This is a randomized, fixed-dose, double-blind, multicenter trial to investigate the safety and efficacy of AR19 in the treatment of ADHD in adults from 18 through 55 years of age. Safety parameters and therapeutic effect will be evaluated throughout the trial. A target of 312 subjects is set for enrollment. Once subjects are determined to meet all inclusion criteria and were screened, they will be randomized to 20 or 40 mg AR19 daily or placebo.

03

Conditions studied

  • Attention Deficit Hyperactivity Disorder
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is male or female between 18 and 55 years of age, inclusive, at the time of Screening.
  2. Meets criteria for diagnosis of ADHD using Conners' Adult ADHD Diagnostic Interview for (DSM-IV™) adapted for DSM-5™ (CAADID), including onset of ADHD symptoms before the age of 12.
  3. Has an AISRS total score of ≥26 at Visit 2.
  4. Has a clinician-administered Clinical Global Impression-Severity (CGI-S) score of 4 or greater at Visit 2.
  5. In the clinical judgment of the Investigator, the subject needs pharmacological treatment for ADHD.
  6. Must read and write English at a level sufficient to provide written and to complete study-related materials.
  7. For subjects currently on a stable dose of allowed non-ADHD medication, there will be no expected changes in subject's medications during the study with the exception of medications listed in Section 5.9.2.
  8. Males and females who are fertile and sexually active with a partner of the opposite sex must adhere to requirements for the duration of the study as follows:

    • Females of must agree to be abstinent or to use highly effective forms of contraception.
    • Females of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or for at least 12 months do not require contraception during the study.
    • Males , with female partners of childbearing potential must agree to be abstinent or use a medically acceptable form of contraception from screening through the end of study.

Exclusion criteria

Exclusion Criteria:

  1. Has a primary psychiatric diagnosis other than ADHD.
  2. Has any other current secondary or co-morbid medical, psychiatric, or social condition which, in the opinion of the investigator, might compromise subject safety, or is likely to interfere with protocol compliance or to confound the assessment of safety or efficacy.
  3. Has a history or current symptoms of bipolar disorder, schizophrenia, or psychotic disorder.
  4. Has cognitive impairment in the clinical judgment of the Investigator.
  5. Has a (BMI) of \<17 or ≥39 kg/m2.
  6. Has a Screening or Baseline triplicate-average blood pressure of ≥139 millimeter of mercury (mmHg) systolic or ≥89 mmHg diastolic. Blood pressure will be taken in triplicate, and the average will be used for evaluating entry criteria.
  7. Is pregnant or breastfeeding, or is planning to become pregnant during the study.
  8. Has a history of any of the following disorders:

    • Seizure disorder (excluding a history of isolated febrile seizures \<6 years old),
    • Inadequately or not treated hypertension is defined as a subject who has blood pressure indicative of Stage 2 hypertension (systolic pressure ≥140 mmHg or diastolic pressure ≥90 mmHg). Subjects who are adequately treated must be on a stable dose of antihypertensive medications for 3 months prior to screening and their antihypertensive medications are not anticipated to change.
    • Untreated thyroid disease. Subjects with a history of thyroid disease who have been on a stable dose of thyroid hormone for at least three months are eligible to participate if their thyroid-stimulating hormone (TSH) does not fall in the excluded range, shown below in 14.
    • Glaucoma
    • Tourette's disorder, or chronic tics.
    • Subjects who have had gastrointestinal surgery or a procedure that involves:

      • Excision or partial excision of the esophagus, stomach, small and large intestine, liver, pancreas or biliary tree. Appendectomy, cholecystectomy and/or removal of gallstones in the bile ducts (as long as the ducts remain intact) are exceptions.
      • Reduction of the stomach volume without excision or partial excision of the stomach (e.g. restrictive surgery/procedure)
      • Obesity treatments that can affect gastrointestinal (GI) capacity or function, such as electrical stimulation systems, gastric balloon systems, and gastric external drainage systems
  9. Has (ECG) or clinical evidence of the following:

    • Fridericia's wave interval (QTcF) > 470 milliseconds (msec) for females, and > 450 msec for males
    • Atrial or ventricular hypertrophy
    • Intraventricular conduction defects other than incomplete right bundle branch block in the absence of other heart disease
    • Myocardial infarct, ischemia, or symptomatic coronary artery disease within 1 year prior to the Screening Visit
    • Clinically significant atrial or ventricular dysrhythmia; the heart must be in predominantly normal sinus rhythm
    • Second or third degree atrioventricular block
    • Heart failure
    • Functionally significant cardiac structural abnormality or valvular disease
    • Cardiomyopathy
    • Any other cardiovascular condition that the Investigator feels may predispose the subject to cardiovascular events (e.g. myocardial infarction, stroke) or arrhythmia
  10. Known family history of sudden cardiac death in the absence of pre-existing heart disease.
  11. Use of any psychotropic medication within 28 days of the Baseline visit except for ADHD medication. (Sedative hypnotics prescribed as a sleep aid at a stable dose for at least 28 days prior to Baseline, at bedtime only, are allowed during the study.)
  12. Has used prohibited drugs or agents within 28 days of the Baseline visit through Study Visit 7. (Stimulant medications are allowed until 7 days before the Baseline visit.) Non-stimulant ADHD medications (guanfacine, bupropion, clonidine, and/or atomoxetine) are not allowed within 28 days of Visit 2 or at any time during the study. Note: Medications that are being taken for psychiatric or medical disorders other than ADHD should not be discontinued for the purpose of qualifying for study participation unless the medication is deemed medically unnecessary by the prescribing physician.
  13. Has received an drug within 60 days of the Screening visit.
  14. Has an abnormal laboratory test value, vital sign, or other exam finding at Screening or Baseline that, in the opinion of the Investigator, warrants exclusion from the study. In addition, subjects with laboratory values listed below are considered exclusionary:

    • Serum (AST) or alanine transaminase (ALT) >1.5 × (ULN)
    • Serum total >1.5 × ULN unless due to Gilbert's Syndrome
    • Serum creatinine >1.3 × ULN
    • Glycosylated () ≥7.0%.
    • TSH \<0.9 × lower limit of normal (LLN) or TSH >1.2 × ULN
  15. Reports a history of or intolerance to any formulation of amphetamine.
  16. Reports a history of poor therapeutic response to any formulation of amphetamine or methylphenidate despite a clearly adequate trial (including dose and duration).
  17. Is unable to swallow medication in capsule form.
  18. Is unable or unwilling to follow directions of study staff or comply with all the testing and requirements of the protocol.
  19. Has a positive urine drug result at Screening (with the exception of current ADHD stimulant therapy, if any). Note: subjects should be informed that they should not participate in the trial or submit to urine drug testing if they are using any controlled or recreational drug (other than a prescribed stimulant for ADHD), and non-use should be confirmed prior to testing.
  20. Has a positive blood alcohol level at Screening. Note: subjects should be informed that alcohol consumed within 12 hours of screening may result in a positive test.
  21. Has current or known history of drug or alcohol abuse within the past 12 months.
  22. Has a history of (HIV), , or untreated infection. Note: subjects with a history of hepatitis C infection who have been treated and whose hepatitis C virus ribonucleic acid (HCV RNA) is currently undetectable are not excluded.
  23. In the past 12 months, has had an intensity of suicidal ideation of greater than 1or any self-injurious behavior using the Columbia Suicide Severity Rating Scale at the Screening or Baseline visits.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
320 participants (actual)

Study arms

  • Experimental
    Arm 1: 20 mg/day

    Amphetamine Sulfate

    Drug: Amphetamine Sulfate

  • Experimental
    Arm 2: 40 mg/day

    Amphetamine Sulfate

    Drug: Amphetamine Sulfate

  • Placebo comparator
    Arm 3: Placebo

    Placebo, no active drug

    Drug: Placebo

Interventions

  • active experimental AR19

    Also known as: AR19

  • DrugPlacebo

    Matching placebo

    Also known as: inactive drug

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms

    Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.

    Time frame: Week 5 (Visit 7)

Secondary outcomes

  1. Change From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores

    Items are scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points, with 27 points for each subscale (summed). The total score is the sum of the inattentive and hyperactive-impulsive subscales. Higher values represent more severe hyperactivity and/or inattentiveness.

    Time frame: Up to 5 weeks

  2. Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline

    CGI-Severity (CGI-S): The CGI-Severity (CGI-S) asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

    Time frame: Up to 5 weeks

  3. Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline

    "Compared to the patient's condition at admission to the project \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

    Time frame: Up to 5 weeks

  4. Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline

    The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning (GEC) and 9 non-overlapping scales among 2 summary index scales (Metacognition Index \[MI\] and Behavioral Regulation Index \[BRI\]) that assess aspects of executive function and problems with self-regulation from the perspective of the individual. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 70 items yields the GEC raw score (range: 70-210), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline GEC T-score is converted to a change from baseline T-score. A lower change from baseline GEC T-score (\<0) represents a better outcome.

    Time frame: Up to 5 weeks

07

Results

Posted Sep 3, 2024

Participant flow

Participant flow — Overall Study
MilestonePlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)
Started106107107
Completed928787
Not completed142020

Outcome measures

PrimaryChange From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms

Change from baseline in severity of Attention Deficit Hyperactivity (ADHD) symptoms, as measured by the adult ADHD Investigator Symptom Rating Scale (AISRS), with a minimum score of 0, and maximum score of 54. Higher scores indicate more severe symptoms, or a worse outcome.

Time frame:
Week 5 (Visit 7)
Reported as:
Least squares mean · score on a scale
Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms
score on a scalePlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)
Change From Baseline in Severity of Attention Deficit Hyperactivity (ADHD) Symptoms-11.1 ± 1.28-18.2 ± 1.28-18.1 ± 1.27
SecondaryChange From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores

Items are scored as follows: 0 (none), 1 (mild), 2 (moderate), 3 (severe). The maximum total score for the scale is 54 points, with 27 points for each subscale (summed). The total score is the sum of the inattentive and hyperactive-impulsive subscales. Higher values represent more severe hyperactivity and/or inattentiveness.

Time frame:
Up to 5 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Visit 7 in AISRS Hyperactive and Inattentive Subscale Scores
score on a scalePlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)
Hyperactivity/Impulsivity Subscale-5.2 ± 0.61-8.3 ± 0.61-8.0 ± 0.6
Inattentive Subscale-5.9 ± 0.74-9.9 ± 0.74-10.0 ± 0.74
SecondaryChange in Clinical Global Impression of Severity (CGI-S) Score From Baseline

CGI-Severity (CGI-S): The CGI-Severity (CGI-S) asks the clinician one question: "Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?" which is rated on the following seven-point scale: 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients.

Time frame:
Up to 5 weeks
Reported as:
Least squares mean · score on a scale
Change in Clinical Global Impression of Severity (CGI-S) Score From Baseline
score on a scalePlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)
Visit 3 (Week 1)-0.5 ± 0.1-0.9 ± 0.1-1.0 ± 0.1
Visit 4 (Week 2)-0.7 ± 0.12-1.1 ± 0.12-1.3 ± 0.12
Visit 5 (Week 3)-0.8 ± 0.12-1.4 ± 0.12-1.5 ± 0.12
Visit 6 (Week 4)-0.8 ± .12-1.4 ± .12-1.5 ± 0.12
Visit 7 (End of Study/End of Treatment)-0.9 ± .13-1.5 ± .13-1.5 ± .13
SecondaryChange in Clinical Global Impression of Improvement (CGI-I) Score From Baseline

"Compared to the patient's condition at admission to the project \[prior to medication initiation\], this patient's condition is: 1=very much improved since the initiation of treatment; 2=much improved; 3=minimally improved; 4=no change from baseline (the initiation of treatment); 5=minimally worse; 6= much worse; 7=very much worse since the initiation of treatment."

Time frame:
Up to 5 weeks
Reported as:
Least squares mean · score on a scale
Change in Clinical Global Impression of Improvement (CGI-I) Score From Baseline
score on a scalePlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)
Visit 3 (Week 1)3.3 ± 0.12.9 ± 0.12.8 ± 0.1
Visit 4 (Week 2)3.2 ± 0.112.6 ± 0.112.4 ± 0.11
Visit 5 (Week 3)3.0 ± 0.112.6 ± 0.112.4 ± 0.11
Visit 6 (Week 4)3.1 ± 0.112.5 ± 0.112.4 ± 0.11
Visit 7 (End of Study/End of Treatment)3.1 ± 0.122.5 ± 0.122.4 ± 0.12
SecondaryChange in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline

The Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) is a 75-item self-rating scale that assesses overall functioning (GEC) and 9 non-overlapping scales among 2 summary index scales (Metacognition Index \[MI\] and Behavioral Regulation Index \[BRI\]) that assess aspects of executive function and problems with self-regulation from the perspective of the individual. Subjects rate each item on a 3-point scale (1=Never, 2=Sometimes, or 3=Often) based on their experience in past month. The sum of 70 items yields the GEC raw score (range: 70-210), which is converted to a T-score (normative population mean=50 and standard deviation=10; T-score ≥ 65 is considered abnormally elevated). The post-baseline GEC T-score is converted to a change from baseline T-score. A lower change from baseline GEC T-score (\<0) represents a better outcome.

Time frame:
Up to 5 weeks
Reported as:
Least squares mean · T-Score
Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) Score From Baseline
T-ScorePlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)
Global Executive Composite T-Score-7.4 ± 1.33-13.6 ± 1.35-14.6 ± 1.31
Behavioral Regulation Index T-Score-6.4 ± 1.15-11.5 ± 1.17-12.8 ± 1.14
Metacognition Index (MI) T-Score-7.2 ± 1.32-13.4 ± 1.37-14.2 ± 1.33
Inhibit T-Score-7.1 ± 1.22-11.3 ± 1.25-13.0 ± 1.21
Self-Monitor T-Score-5.2 ± 1.10-10.6 ± 1.12-11.9 ± 1.09
Plan/Organize T-Score-6.9 ± 1.30-12.2 ± 1.33-12.9 ± 1.29
Shift T-Score-4.8 ± 1.13-9.8 ± 1.16-10.4 ± 1.13
Initiate T-Score-5.0 ± 1.16-10.3 ± 1.19-11.2 ± 1.15
Task Monitor T-Score-6.8 ± 1.33-12.6 ± 1.36-13.5 ± 1.32
Emotional Control T-Score-3.9 ± 0.94-7.1 ± 0.96-8.0 ± 0.93
Working Memory T-Score-7.5 ± 1.36-13.4 ± 1.40-14.8 ± 1.36
Organization of Materials T-Score-4.3 ± 1.09-9.5 ± 1.12-10.0 ± 1.09

Adverse events

Collected over Collection of AE information started with the first dose of the study drug (Day 2) and continued through the post-withdrawal follow-up phone call (i.e., 7 days after Visit 7 [Week 5]). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/106 (0%)0/106 (0%)19/106 (17.9%)
Amphetamine Sulfate (20 mg/Day)0/107 (0%)0/107 (0%)46/107 (43%)
Amphetamine Sulfate (40 mg/Day)0/107 (0%)0/107 (0%)55/107 (51.4%)
Most frequent other events
Most frequent other events
EventPlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)
HeadacheNervous system disorders13/10614/10712/107
Decreased AppetiteMetabolism and nutrition disorders5/10611/10714/107
Dry MouthGastrointestinal disorders4/1066/10712/107
InsomniaPsychiatric disorders4/1069/10710/107
PalpitationsCardiac disorders2/1062/1077/107
NasopharyngitisInfections and infestations6/1065/1073/107
TachycardiaCardiac disorders0/1066/1074/107

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)Total
Mean34.2 ± 10.7535.6 ± 10.2833.5 ± 9.3534.4 ± 10.15
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)Total
Female525044146
Male545763174
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)Total
Hispanic or Latino14131441
Not Hispanic or Latino929493279
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)Total
American Indian or Alaska Native1001
Asian6129
Native Hawaiian or Other Pacific Islander0011
Black or African American13131541
White808988257
More than one race0000
Unknown or Not Reported64111
ADHD Type
ADHD Type(Participants)PlaceboAmphetamine Sulfate (20 mg/Day)Amphetamine Sulfate (40 mg/Day)Total
Inattentive14192053
Hyperactive/Impulsive1001
Combined918887266
08

Study locations

31 sites
  • 114: Pharmacology Research Institute
    Encino, California 91316, United States
  • 133: Collaborative Neuroscience Network
    Garden Grove, California 92845, United States
  • 124: Pharmacology Research Institute
    Newport Beach, California 92660, United States
  • 121: CT Clinical Research Associates
    Cromwell, Connecticut 06416, United States
  • 108: Meridien Research
    Bradenton, Florida 34201, United States
  • 103: Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • 129: Sarkis Clinical Trials
    Gainesville, Florida 32607, United States
  • 105: Meridien Research
    Lakeland, Florida 33805, United States
  • 120: Meridien Research
    Maitland, Florida 32751, United States
  • 130: Medical Research Group of Central Florida
    Orange City, Florida 32763, United States
  • 123: APG Research, LLC
    Orlando, Florida 32803, United States
  • 115: Clinical Neuroscience Solutions (CNS), Inc.
    Orlando, Florida 32806, United States
  • 104: Northwest Behavioral Research Center
    Marietta, Georgia 30060, United States
  • 131: Advanced Clinical Research, Inc.
    Meridian, Idaho 86342, United States
  • 113: Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • 134: Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • 128: Clinical Neurophysiology Services
    Sterling, Michigan 48314, United States
  • 107: Center for Psychiatry and Behavioral Medicine
    Las Vegas, Nevada 89128, United States
  • 116: Alliance - Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • 127: Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • 101: Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • 118: Bioscience Research, LLC
    Mount Kisco, New York 10549, United States
  • 119: Neurobehavioral Clinical Research, Inc.
    Canton, Ohio 44718, United States
  • 106: Summit Research Network
    Portland, Oregon 97210, United States
  • 126: Coastal Carolina Research
    Mount Pleasant, South Carolina 29464, United States
  • 102: Clinical Neuroscience Solutions (CNS), Inc.
    Memphis, Tennessee 38119, United States
  • 132: Research Strategies of Memphis
    Memphis, Tennessee 38119, United States
  • 125: Biobehavioral Research of Austin
    Austin, Texas 78759, United States
  • 110: FutureSearch Trials of Dallas
    Dallas, Texas 75231, United States
  • 117: Houston Clinical Trials, LLC
    Houston, Texas 77005, United States
  • 109: Ericksen Research and Development
    Clinton, Utah 84405, United States
09

References and documents

Publications

  • Faraone SV, Childress A, Caras S, Arnold VK, Montano CB, Sarkis EH, Cutler AJ, Young JL. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AR19, a Manipulation-Resistant Formulation of Amphetamine Sulfate, in Adults With Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry. 2021 Aug 24;82(5):21m13927. doi: 10.4088/JCP.21m13927. PubMed 34428356 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Apr 2019, 6 months.

Results were first posted in Sep 2024, 5 years 4 months after primary completion. A results delay was requested in Aug 2020.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2018
First posted
Sep 6, 2018
StartActual
Sep 18, 2018
Primary completionActual
Apr 12, 2019
CompletionActual
Apr 12, 2019
Results delay requested
Aug 31, 2020
Results first posted
Sep 3, 2024
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03659929
Responsible party
Sponsor
First posted
Sep 6, 2018
Start date
Sep 18, 2018
Primary completion
Apr 12, 2019
Completion
Apr 12, 2019
Results posted
Sep 3, 2024
Last update
Sep 3, 2024

Study contacts

Steven Caras, MD, PhD
study director · Arbor Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amphetamine

Start the discussion